Advances in combined radiation therapy for the management of rectal cancer

Expert Review of Anticancer Therapy

Volumn 3, Issue 4, 2003, Pages 471-483

  Kachnic, Lisa A ^a   Shih, Helen A ^b   Willett, Christopher G ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Adjuvant therapy; Combined modality therapy; Radiation therapy; Rectal cancer

Indexed keywords

AMIFOSTINE; BEVACIZUMAB; CAPECITABINE; CELECOXIB; CHLOROETHYLNITROSOUREA DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IRINOTECAN; LEVAMISOLE; LOMUSTINE; METHYL N (2 CHLOROETHYL) N' CYCLOHEXYL N NITROSOUREA; OXALIPLATIN; RALTITREXED; UFT; UNCLASSIFIED DRUG; VINCRISTINE;

ANUS SPHINCTER; ASTHENIA; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; EUROPE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; MULTIMODALITY CANCER THERAPY; PREOPERATIVE TREATMENT; RASH; RECTUM CANCER; REVIEW; WESTERN HEMISPHERE;

EID: 0042510801     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.3.4.471     Document Type: Review

References (117)

1. Jermal A, Thomas A, Murray T et al. Cancer Statistics, 2002. CA Cancer J. Clin. 52, 2347 (2002).
2. Rich T, Gunderson LL, Lew R et al. Patterns of recurrence of rectal cancer after potentially curative surgery. Cancer 52, 1317-1329 (1983).
3. Mendenhall WM, Million RR, Pfaff WW. Patterns of recurrence in adenocarcinoma of the rectum and rectosigmoid treated with surgery alone: indications in treatment planning with adjuvant radiation. Int. J Radiat. Oncol. Biol. Phys. 9, 977-985 (1983).
4. Piliphen SJ, Heilweil M, Quan SH et al. Patterns of pelvic recurrence following definitive resections of rectal cancer. Cancer 53, 1354-1362 (1984).
5. Gastrointestinal Tumor Study Group. Prolongation of the disease-free survival in surgically treated rectal carcinoma. N. Engl. J. Med. 312, 465-1472 (1985).
6. Krook JE, Moertel CG, Gunderson LL et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N. Engl. J. Med. 324, 709-715 (1991).
7. National Institutes of Health Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 264, 1444-1450 (1990).
8. Fisher B, Wolmark N, Rockette H et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J. Natl Cancer Inst. 80, 21-29 (1988).
9. Wolmark N, Wieand S, Hyams DM et al. Randomized trial of postoperative adjuvant chemotherapy with or without radiation for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J. Natl Cancer Inst. 92, 388-396 (2000).
10. Gastrointestinal Tumor Study Group. Radiation therapy and 5-FU with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. J. Clin. Oncol. 10, 549-557 (1992).
11. O'Connell MJ, Martenson JA, Wieand HS et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion 5-FU with radiation therapy after curative surgery. N. Engl. J. Med. 331, 502-507 (1994).
12. Tepper JE, O'Connell MJ, Niedzwiecki DR et al. Adjuvant therapy in rectal cancer: analysis of stage, sex and local control: final report of Intergroup 0114. J. Clin. Oncol. 20, 1744-1750 (2002).
13. Smalley SR, Benedetti J, Williamson S et al. Intergroup 0144: Phase III trial of 5-FU-based chemotherapy regimens plus radiotherapy (XRT) in postoperative adjuvant rectal cancer. Bolus 5-FU versus prolonged venous infusion (PVI) before and after XRT + PVI versus bolus 5-FU + leucovorin (LV) + levamisole (LEV) before and after XRT + bolus 5-FU + LV. Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 1006).
14. Lee J-H, Lee J-H, Ahn J-H et al. Randomized trial of postoperative adjuvant therapy in Stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: a preliminary report. J. Clin. Oncol. 20, 1751-1758 (2002).
15. Willett CG, Badizaadegan K, Ancukiewicz M et al. Prognostic factors in Stage T3N0 rectal cancer: do all patients require postoperative irradiation and chemotherapy? Dis. Colon Rectum , 167-173 (1999).
16. Merchant NB, Guillem JG, Paty PB et al. T3N0 rectal cancer: results following sharp mesorectal excision and no adjuvant therapy. J. Gastrointest. Surg. 3, 6-647 (1999).
17. Heald RJ, Ryall RDH. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1, 1479-1482 (1986).
18. Heald RJ, Moran BJ, Ryall RD et al. Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997. Arch. Surg. 133, 894-899 (1998).
19. Kafka NJ, Enker WE. Total mesorectal excision with autonomic nerve preservation: a new foundation for the evaluation of multi-disciplinary adjuvant therapy in the management of rectal cancers. Ann. Chir 53, 996-1002 (1999).
20. Leong AFPK. Selective total mesorectal excision for rectal cancer. Dis. Colon Rectum 43, 1237-12 (2000).
21. Enker WE, Merchant N, Cohen AM et al. Safety and efficacy of low anterior resection for rectal cancer: 681 consecutive cases from a specialty service. Ann. Surg. 230, 544-552 (1999).
22. Kapiteijn E, Marijnen CA, Nagtegaal ID et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N. Engl. J. Med. 345, 638-646 (2001).
23. Bleday R, Steele G Jr. Current protocols and outcome of local therapy for rectal cancer. Surg. Oncol. Clin. North Am. 9, 751-758 (2000).
24. Chakravarti A, Compton C, Shellito P et al. Long-term follow-up of patients with rectal cancer managed by local excision with and without adjuvant irradiation. Ann. Surg. 230, 49-54 (1999).
25. Paty PB, Nash GM, Baron P et al. Long-tem results of local excision for rectal cancer. Ann. Surg. 236, 522-530 (2002).
26. Steele GD, Herndon JE, Bleday R et al. Sphincter-sparing treatment for distal rectal adenocarcinoma. Ann. Surg. Oncol. 6, 433-441 (1999).
27. Russell AH, Harris J, Rosenberg PJ et al. Anal sphincter conservation for patients with adenocarcinoma of the distal rectum: long-term results of radiation therapy oncology group protocol 89-02. Int. J. Radiat. Oncol. Biol Phys. 46, 313-322 (2000).
28. Blair S, Ellehorn JD. Transanal excision for low rectal cancers is curative in early-stage disease with favorable histology. Am. Surg. 66, 817-820 (2000).
29. No authors listed. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N. Engl. J. Med. 336, 980-987 (1997).
30. Dahlberg M, Glimelius B, Graf W et al. Preoperative irradiation affects functional results after surgery for rectal cancer: results from a randomized study. Dis. Colon Rectum 41, 543-549 (1998).
31. Mendenhall WM, Bland KI, Copeland EM et al. Does preoperative radiation therapy enhance the probability of local control and survival in high-risk distal rectal cancer. Ann. Surg. 215, 696-706 (1992).
32. Myerson RJ, Michalsi JM, King ML et al. Adjuvant radiation therapy for rectal carcinoma: predictors of outcome. Int. J. Radiat. Oncol. Biol. Phys. 32, 41-50 (1995).
33. Rich TA, Skipper JM, Ajani JA et al. Preoperative infusional chemoirradiation for Stage T3 rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 32, 1025-1029 (1995).
34. Chan RS, Tyler DS, Anscher MS et al. Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum. Ann. Surg. 221, 779-787 (1995).
35. Minsky BD, Cohen AM, Kemeny N et al. Enhancement of radiation-induced downstaging of rectal cancer by 5-FU and high-dose leucovorin chemotherapy. J. Clin. Oncol. 10, 79-84 (1992).
36. Wagman R, Minsky BD, Cohen AM et al. Sphincter prevention with preoperative radiation therapy and coloanal anastomosis. Int. J. Radiat. Oncol. Biol. Phys. , 51-57 (1998).
37. Rouonet P, Fabre J, Dubois J et al. Conservative surgery for low rectal cancer after high dose radiation. Am. Surg. 221, 67-73 (1995).
38. Mohiuddin M, Rozine W, Marks G et al. High dose preoperative radiation and the challenge of sphincter-preservation surgery for cancer of the distal rectum. Int. J Radiat. Oncol. Biol. Phys. , 569-574 (1998).
39. Bosset JF, Magnin V, Maingon P et al. Preoperative radiochemotherapy in rectal cancer: long-term results of a Phase II trial. Int. J. Radiat. Oncol. Biol. Phys. 46, 323-327 (2000).
40. Allal AS, Bieri S, Pelloni A et al. Sphincter-sparing surgery after preoperative radiotherapy for low rectal cancers: feasibility, oncologic results and quality of life outcomes. Br. J. Cancer 82, 1131-1137 (2000).
41. Bosset J-F, Calais G, Daban A et al. Does the addition of chemotherapy to preoperative radiation increase acute toxicity in patients with rectal cancer: report of 22921 EORTC Phase III trial. Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 1179).
42. Mohiuddin M, Regine WF, John WJ et al. Preoperative chemoradiation in fixed distal rectal cancer: dose time factors for pathologic complete response. Int. J. Radiat. Oncol. Biol. Phys. 46, 883-888 (2000).
43. Francois Y, Nemoz CJ, Baulieux J et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J. Clin. Oncol. 17, 2396-22 (1999).
44. Hyams DM, Mamounas EP, Petrelli N et al. A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum. A progress report of the National Surgical Adjuvant Breast and Bowel Project protocol R-03. Dis. Colon Rectum , 131-139 (1997).
45. Sauer R, Fietkau R, Wittekind C et al. Adjuvant versus neoadjuvant radiochemotherapy for locally advanced rectal cancer: a progress report of a Phase III randomized trial. Strahlenther Onkol. 177, 173-181 (2001).
46. Miller AR, Martenson JA, Nelson H et al. The incidence and clinical consequences of treatment-related bowel injury. Int. J. Radiat. Oncol. Biol. Phys. 43, 817-825 (1999).
47. Baglan KL, Frazier RC, Yan D et al. The dose-volume relationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 52, 176-183 (2002).
48. Gunderson LL, Russell AH, Llewellyn HJ et al. Treatment planning for colorectal cancer: radiation and surgical techniques and value of small-bowel films. Int. J. Radiat. Oncol. Biol. Phys. 11, 1379-1393 (1985).
49. Minsky BD. Pelvic radiation therapy in rectal cancer: technical considerations. Semin. Radiat. Oncol. 3, 42-47 (1993).
50. Willett CG. Technical advances in the treatment of patients with rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 45, 1107-1108 (1999).
51. Das IJ, Lanciano RM, Movsas B et al. Efficacy of a belly board device with CT-simulation in reducing small bowel volume within pelvic irradiation fields. Int. J. Radiat. Oncol. Biol. Phys. 39, 67-76 (1997).
52. Kolbl O, Richter S, Flentje M. Influence of treatment technique on dose-volume histogram and normal tissue complication probability for small bowel and bladder. A prospective study using a 3D planning system and a radiobiological model in patients receiving postoperative pelvic radiation. Strahlenther Onkol. 176, 105-111 (2000).
53. Capirci C, Valvo F, Salviato S et al. Concurrent boost radiotherapy as preoperative treatment for locally advanced rectal carcinoma: a new beam arrangement. Tumori 88, 325-330 (2002).
54. Robertson JM, Yan D, Girimonte PE et al. The potential benefit of intensity modulated radiation therapy (IMRT) for rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 45(Suppl. 3), 248 (1999).
55. Nutting CM, Convery DJ, Cosgrove VP et al. Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 48, 649-656 (2000).
56. Janjan NA, Crane CN, Feig BW et al. Prospective trial of preoperative concomitant boost radiotherapy with continuous infusion 5-fluorouracil for locally advanced rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 47, 713-718 (2000).
57. Coucke PA, Cuttat JF, Mirimanoff RO. Adjuvant postoperative accelerated hyperfractionated radiotherapy in rectal cancer: a feasibility study. Int. J. Radiat. Oncol. Biol. Phys. 27, 885-889 (1993).
58. Coucke PA, Sartorelli B, Cuttat JF et al. The rationale to switch from postoperative hyperfractionated accelerated radiotherapy to preoperative hyperfractionated accelerated radiotherapy in rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 32, 181-188 (1995).
59. Allal AS, Bieri S, Brundler MA et al. Preoperative hyperfractionated radiotherapy for locally advanced rectal cancers: a Phase I-IIs trial. Int. J. Radiat. Oncol. Biol. Phys. 54, 1076-1081 (2002).
60. Ohnishi ST, Ohnishi T. Glick JH et al. In vitro study on the anti-oxidant activities of amifostine (wr-2721). Proc. Am. Assoc. Cancer Res. 33, 419 (1992).
61. Calabro-Jones PM, Fahey RC, Smoluk GD, et al. Alkaline phophatase promotes radioprotection and accumulation of WR-1065 in V79-171 cellls incubated in medium containing WR-2721. Int. J Radiat. Oncol. Biol. Phys. 47, 23-27 (1985).
62. Liu T, Liu Y, He S et al. Use of radiation with or without WR-2721 in advanced rectal cancer. Cancer 69, 2820-2825 (1992).
63. Antonadou D, Athanassiou H, Sarris G et al. Randomized Phase III trial of chemoradiation treatment +/- amifostine in patients with colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 1176).
64. Dunst J, Semlin S, Pigorsch S et al. Intermittent use of amifostine during postoperative radiochemotherapy and acute toxicity in rectal cancer patients. Strahlenther Onkol. 176, 416-421 (2000).
65. Myerson R, Zobeiri I, Birnbaum E et al. Early results from a Phase I-II radiation dose-escalation study with concurrent amifostine and infusional 5-fluorouracil chemotherapy for preoperative treatment of unresectable or locally recurrent rectal cancer. Semin. Oncol. 29(Suppl. 19), 29-33 (2002).
66. Blackstock A, Hess S. Oxaliplatin: in vitro and in vivo evidence of its radiosensitizing activity - preclinical observations relevant to ongoing clinical trials. Proc. Am. Assoc. Cancer Res. 41, 53 (2000) (Abstract).
67. Freyer G, Bossard N, Romestaing P et al. Addition of oxaliplatin to continuous fluorouracil, 1-folinic acid and concomitant radiotherapy in rectal cancer: the Lyon R 97-03 Phase I trial. J. Clin. Oncol. 19, 2433-2438 (2001).
68. Gérard J-P, Chapet O, Nemoz C et al. Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 Phase II trial. J Clin. Oncol. 21, 1119-1124 (2003).
69. Valentini V, Morganti AG, Romestaing P et al. Raltitrexed and oxaliplatin preliminary results of a Phase II study of chemoradiation with preoperative treatment of Stage II/III resectable rectal cancer. Proc. Am. Soc. Clin. Oncol. 21, 151 (2002) (Abstract).
70. Schele C, Frisco ML, Puriarella S et al. A Phase I-II study of weekly oxaliplatin, 5-FU continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. Proc. Am. Soc. Clin. Oncol. 21 (2002).
71. Rosenthal DI, Catalano D, Haller DG et al. ECOG 1297: a Phase I study of preoperative radiation therapy (RT) with concurrent protracted continuous infusion 5-FU and dose escalating oxaliplatin followed by surgery, adjuvant 5-FU and leucovorin for locally advanced (T3/4) rectal adenocarcinoma. Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 1094).
72. Omura M, Torigoe S, Kubota N. SN-38, a metabolite of the camptothecan derivative CPT-11, potentiates the cytotoxic effect of radiation in human colon adenocarcinoma cells grown as spheroids. Radiother. Oncol. 43, 197-201 (1997).
73. Mitchell E, Anne P, Fry R et al. Chemoradiation with CPT-11, 5FU in neoadjuvant treatment of locally advanced or recurrent adenocarcinoma of the rectum: a Phase I/II study update. Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 1052).
74. Mehra VK, Cho C, Ford JM et al. Phase II trial of preoperative 3D conformal radiotherapy, protracted venows infusion 5-fluorouracil and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 55, 132-137 (2003).
75. Cocconi G, Cunningham D, Van Cutsem E et al. Open, randomized, multicenter trial of raltitrexed versus fluofouracil plus high-dose leucovorin in patients with advanced colorectal cancer. J. Clin. Oncol. 16, 2943-2952 (1998).
76. James RD, Botwood N, Vernon CC et al. Raltitrexed plus radiotherapy for the treatment of unresectable/recurrent rectal cancer: a Phase I study. Ann. Oncol. 14, 570-573 (2003).
77. Valentini V, Doglietto GB, Morganti AG et al. Preoperative chemoradiation with raltitrexed (Tomudex) for T2/N+ and T3/N+ rectal cancers: a Phase I study. Eur. J. Cancer 37, 2050-2055 (2001).
78. Sato A, Kurihara M, Horikoshi N et al. Phase II study of raltitrexed (Tomudex) in chemotherapy-pretreated patients with advanced colorectal cancer. Tomudex Cooperative Study Group. Anticancer Drugs 10, 741-748 (1999).
79. Martoni A, Mini E, Pinto C et al. Oxaliplatin plus raltitrexed in the treatment of patients with advanced colorectal cancer: a Phase II study. Anticancer Res. 23, 687-691 (2003).
80. Huang P, Chubb S, Hertel LW et al. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res. 51, 6110-6117 (1991).
81. Moore DF Jr, Pazdur R, Daugherty K et al. Phase II study of gemcitabine in advanced colorectal adenocarcinoma. Invest. New Drugs 10, 323-325 (1992).
82. Mani S, Kugler JW, Knost JA et al. Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: minimal activity in colorectal cancer. Invest. New Drugs 16, 275-278 (1998).
83. Madajewicz S, Hentschel P, Burns P et al. Phase I chemotherapy study of biochemical modulation of folinic acid and fluorouracil by gemcitabine in patients with solid tumor malignancies. J. Clin. Oncol. 15, 3553-3557 (2000).
84. Hoff PM, Royce M, Medgyesy D et al. Oral fluoropyrimidines. Semin. Oncol. 26, 6-646 (1999).
85. Hoff PM, Pazdur R, Benner SE et al. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. Anticancer Drugs 9, 479-490 (1998).
86. Douillard JY, Hoff PM, Skillings JR et al. Multicenter Phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 20, 3605-3616 (2002).
87. Carmichael J, Popiela T, Radstone D et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 20, 617-627 (2002).
88. Hoff PM, Janjan N, Saad ED et al. Phase I study of preoperative oral uracil and tegafur plus leucovorin and radiation therapy in rectal cancer. J. Clin. Oncol. 18, 3529-3534 (2000).
89. De la Torre A, Ramos S, Valcarcel FJ et al. Phase II study of radiochemotherapy with UFT and low-dose oral leucovorin in patients with unresectable rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 45, 629-634 (1999).
90. Feliu J, Calvillo J, Escribano A et al. Neoadjuvant therapy of rectal carcinoma with UFT-leucovorin plus radiotherapy. Ann. Oncol. 13, 730-736 (2002).
91. Dunst J, Reese T, Sutter T et al Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J. Clin. Oncol. 20, 3983-3991 (2002).
92. Dunst J, Reese T, Hoelscher V et al. Capecitabine combined with radiotherapy as neoadjuvant treatment of locally advanced rectal cancer. Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 1113).
93. Kim J-S, Kim J-S, Cho M-J et al. Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 54, 3-8 (2002).
94. Milas L, Kishi K, Hunter N et al. Enhancement of tumor response to γ-radiation by an inhibitor of cyclooxygenase-2 enzyme. J. Natl Cancer Inst 91, 1501-1504 (1999).
95. Arteaga CL. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin. Oncol 29(Suppl. 14), 3-9 (2002).
96. Joo YE, Kim HS, Min SW et al. Expression of cyclooxygenase-2 protein in colorectal carcinomas. Int. J. Gastrointest. Cancer 31, 147-154 (2002).
97. Giralt J, Eraso A, Armengol M et al. Epidermal growth factor receptor is a predictor of tumor response in locally advanced rectal cancer patients treated with preoperative radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 54, 1460-1465 (2002).
98. Baselga J, Rischin D, Ranson M et al. Phase I safety, pharmacokinetic and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Oncol. 20, 4292-4302 (2002).
99. Ranson M, Hammond LA, Ferry D et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well-tolerated and active in patients with solid, malignant tumors: results of a Phase I trial. J. Clin. Oncol. 20, 22-2250 (2002).
100. Herbst RS, Maddox AM, Rothenberg ML et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD 1839 is generally well-tolerated and has activity in non-small cell lung cancer and other solid tumors: results of a Phase I study. J. Clin. Oncol. 20, 3815-3825 (2002).
101. Jain RK. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin. Oncol. 29(Suppl. 16), 3-9 (2002).
102. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin. Oncol. 29(Suppl. 16), 10-14 (2002).
103. Funaki H, Nishimura G, Harada S et al. Expression of vascular endothelial growth factor D is associated with lymph node metastasis in human colorectal carcinoma. Oncology 64, 416-422 (2003).
104. Cascinu S, Graziano F, Catalano V et al. An analysis of p53, Bax and vascular endothelial growth factor expression in node-positive rectal cancer. Relationships with tumour recurrence and event-free survival of patients treated with adjuvant chemoradiation. Br. J. Cancer 86, 744-749 (2002).
105. Bruns CJ, Liu W, Davis DW et al. Vascular endothelial growth factor is an in vitro survival factor for tumor endothlium in a murine model of colorectal carcinoma liver metastases. Cancer 89, 488-499 (2000).
106. Hurwitz H, Fehrenbacher L, Cartwright T et al. Bevacizumab (Avastin, a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a Phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc. Am. Soc. Clin. Oncol. 22, 2107 (2003).
107. Janjan NA, Crane C, Feig BW et al. Improved overall survival among responders to preoperativc chemoradiation for locally advanced rectal cancer. Am. J. Clin. Oncol. 24, 107-112 (2001).
108. Mohiuddin M, Hayne M, Regine WF et al. Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers. Int. J. Radiat. Oncol. Biol. Phys. 48, 1075-1080 (2000).
109. Willett CG, Warland G, Hagan MP et al. Tumor proliferation in rectal cancer following preoperative irradiation. J. Clin. Oncol. 13, 1417-1424 (1995).
110. Lammering G, Taher MM, Gruenagel H et al. Alteration of DNA ploidy status and cell proliferation induced by preoperative radiotherapy is a prognostic factor in rectal cancer. Clin. Cancer Res. 6, 3215-3222 (2000).
111. Fu CG, Tominaga O, Nagawa H et al. Role of p53 and p21 /WAF1 detection in patient selection for preoperative radiotherapy in rectal cancer patients. Dis. Colon Rectum 41, 68-74 (1998).
112. Tannapfel A, Nublein S, Fietkau R et al. Apoptosis, proliferation, bax, bcl-2 and p53 status prior to and after preoperative radiochemotherapy for locally advanced rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 41, 585-591 (1998).
113. Elsaleh H, Robbins P, Joseph D et al. Can p53 alterations be used to predict tumour response to pre-operative chemotherapy in locally advanced rectal cancer? Radiother. Oncol. 56, 239-244 (2000).
114. Giralt J, Eraso A, de Torres I et al. Epidermal growth factor is a predictor of tumor response in locally advanced rectal cancer patients treated with preoperatice radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 51, 10 (2001).
115. Qiu H, Sirivongs P, Rothenberger M et al. Molecular prognostic factors in rectal cancer treated by radiation and surgery. Dis. Colon Rectum 43, 451-459 (2000).
116. Edler D, Hallatrom M, Johnson PG et al. Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer. Clin. Cancer Res. 6, 1378-1384 (2000).
117. Leichman CG, Lenz H, Leichman L et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J. Clin. Oncol 15, 3223-3229 (1997).